Skip to main content
Surgical Case Reports

Table 1 Characteristics of 77 SPN patients with malignant behavior (distant metastasis, recurrence and/or invasion) in the literature

From: Multidisciplinary treatment of advanced or recurrent solid pseudopapillary neoplasm of the pancreas: three case reports

Patient characteristics

Number of patients

References

Age, median years (range)

24 (7–66)*

[4, 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]

Male/female/unknown

8 / 54 / 15

[4, 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]

Location of main tumor, head/body or tail/unknown

13 / 36 / 28

[4, 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]

Metastatic and recurrent site (%)

  

 Liver

44 (57.1)

[4, 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]

 Lung

3 (3.9)

[4, 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]

 Peritoneum

19 (24.7)

[4, 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]

 Lymph node

9 (11.7)

[4, 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]

 Local

18 (23.4)

[4, 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]

 Others

6 (7.8)

[4, 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]

Non-surgical treatment effect, tumor reduction/no response/missing data (total number)

  

 GEM-based regimen

0 / 6 / 4 (10)

[10, 17, 19, 21, 23, 29]

 CDDP-based regimen

2 / 2 / 2 (6)

[10, 17, 18]

 5-FU-based regimen

0 / 3 / 2 (5)

[8, 10, 20]

 CDDP + 5-FU

2 / 0 / 3 (5)

[10, 25, 26]

 Interferon

0 / 1 / 2 (3)

[10, 32]

 Tamoxifen

0 / 2 / 0 (2)

[8, 10]

 GEM + CDDP

1 / 1 / 0 (2)

[10, 31]

 Somatostatin

0 / 1 / 0 (1)

[10]

 Capecitabine

0 / 1 / 0 (1)

[10]

 Paclitaxel

0 / 1 / 0 (1)

[19]

 Thalidomide

0 / 1 / 0 (1)

[10]

 Imatinib

0 / 1 / 0 (1)

[10]

 Oxaliplatin-based regimen

0 / 1 / 0 (1)

[10]

 Erlotinib

0 / 1 / 0 (1)

[23]

 RFA

0 / 3 / 4 (7)

[7, 10, 17]

 RT

5 / 0 / 0 (5)

[22, 32,33,34,35]

 CRT

0 / 1 / 1 (2)

[10]

 TAI

0 / 1 / 1 (2)

[10, 23]

 TACE

1 / 0 / 1 (2)

[8, 23]

 HIPEC

0 / 1 / 1 (2)

[11, 30]

 TAE

0 / 1 / 0 (1)

[10]

 MCN

0 / 1 / 0 (1)

[10]

 SIRT

0 / 0 / 1 (1)

[17]

 CS-PHP

1 / 0 / 0 (1)

[31]

 Proton beam therapy

1 / 0 / 0 (1)

[29]

  1. GEM gemcitabine, CDDP cisplatin, 5-FU 5-fluorouracil, RFA radiofrequency ablation, RT radiation therapy, CRT chemoradiotherapy, TAI transcatheter arterial infusion, TACE transcatheter arterial chemoembolization, HIPEC hyperthermic intraperitoneal chemotherapy, TAE transcatheter arterial embolization, MCN microwave coagulo-necrotic therapy, SIRT selective internal radiation therapy, CS-PHP chemosaturation with percutaneous hepatic perfusion
  2. *Only 62 patients' data were available
Back to article page